Servier and GAIA extend their deprexis partnership
Hamburg, Tuesday 14 February 2017 18.00 GMT
Servier, the independent international pharmaceutical company, and GAIA, a global pioneer in digital therapy, have signed a partnership to extend the marketing of deprexis®.
Although depression is a widespread condition, with approximately 350 million individuals affected globally (WHO), many patients do not receive adequate treatment, for many different reasons, including stigmatization. “We are pleased that Servier has decided to extend our collaboration to other countries,” said Mario Weiss, CEO and founder of GAIA. “Their expertise in neuropsychiatry will help implement this treatment into actual clinical practice”.
